Although the incidence of colorectal cancer (CRC) has decreased as a result of increased screening and awareness, it still remains a major cause of cancer-related death. Additionally, early detection of CRC recurrence by conventional means such as CT, endoscopy, and CEA has not translated into an improvement in survival. Liquid biopsies, such as the detection circulating tumor DNA (ctDNA), have been investigated as a biomarker for patients with CRC in terms of prognosis and recurrence, as well as their use to guide therapy. In this manuscript, we provide an overview of ctDNA as well as its utility in providing prognostic information, using it to guide therapy, and monitoring for recurrence in patients with CRC. In addition, we discuss the influence the site of disease may have on the ability to detect ctDNA in patients with metastatic CRC.
尽管结直肠癌（CRC）的发病率因筛查和认知度的提高而有所下降，但其仍是癌症相关死亡的主要原因之一。此外，通过CT、内镜和癌胚抗原（CEA）等常规手段早期检测CRC复发并未转化为生存率的改善。液体活检，如检测循环肿瘤DNA（ctDNA），已被研究作为CRC患者预后和复发的生物标志物，并用于指导治疗。本文概述了ctDNA及其在提供预后信息、指导治疗以及监测CRC患者复发方面的应用。此外，我们还讨论了疾病部位对转移性CRC患者ctDNA检测能力可能产生的影响。
肿瘤(癌症)患者之家